34 results about "Solid lipid nanoparticle" patented technology

Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.

The invention discloses a solid lipid nanoparticle-inulin gel compound for targeted therapy of ulcerative colitis and a preparation method of the solid lipid nanoparticle-inulin gel compound, and belongs to the technical field of medicines, the compound comprises inulin gel and solid lipid nanoparticles dispersed in the inulin gel; the solid lipid nanoparticle comprises a glyceride shell, oleic acid coated by the glyceride shell, a medicine with anti-inflammatory and anti-oxidation effects, and cationic lipid, the mass ratio of the oleic acid to the medicine with the anti-inflammatory and anti-oxidation effects to the cationic lipid is 1: (1-1.5): (2.5-3); the drug loading capacity in the solid lipid nanoparticles is 1 to 10 weight percent. According to the compound, the inulin gel serves as a delivery system, functional solid lipid nanoparticles are carried in the compound, intestinal ferroptosis can be reduced, active oxygen can be removed, the compound has the effects of promoting intestinal barrier repair, relieving inflammatory response and the like, and the compound has good application prospects in the aspect of treatment of ulcerative colitis.

Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.

A system for the production of fenoprofen calcium-loaded solid lipid nanoparticles, comprising units for organic phase production, emulsification, homogenization and solvent extraction, configured to produce nanoparticles with controlled size and encapsulation efficiency.

The granulator comprises a machine body and a bearing plate, the bearing plate is installed on one side of the machine body, two sets of electric push rods are installed at the top end of the bearing plate, push arms are installed at the output ends of the electric push rods, a supporting plate is arranged above the electric push rods, and the supporting plate is connected with the bearing plate. The device comprises a supporting plate, the supporting plate is connected with a push arm, a rotating plate is arranged above the supporting plate, a movable shaft is movably installed at the center of the supporting plate and connected with the rotating plate, a driving motor is installed at the bottom end of the supporting plate, a driving shaft is installed at the output end of the driving motor, and the surface of the driving shaft is sleeved with a transmission gear. The surface of the movable shaft on one side of the transmission gear is sleeved with a driven gear. According to the utility model, convenient high-hydraulic-pressure shearing processing of homogenized liquid is realized, the liquid can be conveniently input in sequence, and the liquid homogenizing effect is improved.

The invention discloses a chondroitin sulfate modified dihydromyricetin solid lipid nanoparticle, and belongs to the field of pharmaceutics. The nanoparticle is composed of a solid lipid component, dihydromyricetin encapsulated in the solid lipid component and a chondroitin sulfate targeting ligand modified on the surface. According to the invention, the chondroitin sulfate is specifically combined with the high-expression CD44 receptor on the surface of the hepatic stellate cell, so that the active targeting delivery of the drug to the hepatic fibrosis focus is realized. The nanoparticles have the characteristics of uniform particle size, high encapsulation efficiency and good slow release effect, can significantly improve the enrichment concentration of dihydromyricetin in the liver, enhance the anti-hepatic fibrosis curative effect and reduce the systemic side effects, and have good application prospects in preparation of hepatic fibrosis targeted therapy drugs.

The present invention provides methods for cleaving a SNARE protein by administering an RNA molecule that encodes the light chain of botulinum toxin. The invention also provides pharmaceutical compositions and formulations for administering the therapeutic molecules of the invention. In one embodiment the therapeutic molecule can be an RNA molecule encoding the light chain of botulinum toxin comprised in a lipid nanoparticle, liposome, or solid lipid nanoparticle. The methods can administer the compositions for a variety of therapeutic and cosmetic purposes. The invention also provides methods of synthesizing a toxic substance, for example botulinum toxin.

The present application belongs to the technical field of drug delivery, and relates to a sequential multi-stage targeted delivery system of a probiotic and prebiotic combination for repairing intestinal barriers. The delivery system is a microcapsule MP wrapped with NPs; the NPs are solid lipid nanoparticles formed by wrapping a probiotic with hyaluronic acid coupled small molecule acids as a film material; and the shell material of the microcapsule MP is a prebiotic. By wrapping the probiotic with hyaluronic acid coupled small molecule acids as a film material to form NPs, and then wrapping the NPs with a prebiotic wall material to form a microcapsule, the sequential multi-stage targeting and zonal release of different drugs can be achieved; the repair of the barrier will not have a reverse effect; the intestinal epithelial cell proliferation is promoted to repair the mechanical barrier; the intestinal flora abundance is improved to repair the microbial barrier; the mucus secretion is promoted to repair the chemical barrier; and the immune homeostasis is regulated to repair the immune barrier.

Disclosed herein are formulated and / or co-formulated lipid nanoparticles (LNPs) and solid lipid nanoparticles (SLNPs) comprising TB prodrugs and methods of making the LNPs and the SLNPs. TB prodrug compositions comprising a drug moiety, a lipid moiety, and a linking unit, inhibit ALK5. The TB prodrugs can be formulated and / or co-formulated into liposomes or solid lipid nanoparticles to provide methods of treating cancer, immune disorders, and other diseases by taking advantage of targeted drug delivery vehicles.

To provide formulated and / or co-formulated liposomal compositions containing TFG β antagonist prodrugs useful in the treatment of cancer, and methods thereof.SOLUTION: Disclosed herein are formulated and / or co-formulated liposomes (LNPs) and solid lipid nanoparticles (SLNPs) comprising TB prodrugs, and methods of making said LNPs and SLNPs. TB pro-drug compositions comprise a drug moiety, a lipidic moiety, and a linking unit, and inhibit ALK5. TB prodrugs can be formulated and / or co-formulated into liposomes or solid lipid nanoparticles to provide a method of treating cancer, immunological disorders, and other diseases by utilizing a targeted drug delivery vehicle.SELECTED DRAWING: None

Acid degradable solid lipid nanoparticles comprise PEG conjugated to cholesterol via an acid degradable linkage comprising an azide-benzaldehyde acetal.

Disclosed is a process for the assembly modified solid lipid nanoparticles (m-SLNs) by a process that comprises: (i) (a) a therapeutic amount of one or more psychedelics, (b) a solid lipid at room temperature (25 °C) that can be composed of mono-, di, and tri- glycerides, (c) a primary surfactant, (d) optionally, one or more co-surfactant(s), (e) optionally, the addition of a liquid lipid at room temperature (25 °C), (f) optionally, the incorporation of a targeting moiety for a target receptor to initiate a physiological response. For the species to be considered a m-SLN, it must incorporate component (e) and / or component (f). (ii) high-shear mixing said ingredients in a container to form a coarse suspension product, and (iii) subjecting the coarse suspension through a microfluidic device to produce a modified solid lipid nanoparticle containing a psychedelic(s)

The present disclosure relates to buccal mucoadhesive patch formulation of tacrolimus loaded in the solid lipid nanoparticles and using the polymeric carrier matrix and pharmaceutically acceptable additives to deliver tacrolimus through the trans buccal route to the systemic circulation. The overall exposure to tacrolimus with the tacrolimus buccal mucoadhesive patch formulation of present invention is considerably higher compared to the conventional oral administration for equivalent dose. It provides an immediate and controlled release of tacrolimus by avoiding the first pass metabolism and providing a steady concentration of tacrolimus in the systemic circulation.

Disclosed is a process for the assembly solid lipid nanoparticles (SLNs) by a process that comprises: (a) combining (i) a therapeutic amount of one or psychedelics, (ii) a solid lipid at room temperature (25 °C) that can be composed of mono-, di, and tri-glycerides, (iii) a primary surfactant, (iv) a co-surfactant(s) (b) high-shear mixing said ingredients in a container to form a coarse-emulsion product, and (c) subjecting the coarse-emulsion through a microfluidic device to produce a solid lipid nanoparticle nanoemulsion containing a psychedelic(s).

Disclosed is a process for the assembly solid lipid nanoparticles by a process that comprises: mixing (i) a therapeutic amount of one or more psychedelic agents, (ii) a protein-based drug carrier using desolvation under high-shear mixing conditions to form a coarse-sized particulate product, and passing the coarse-sized particulate product through a microfluidic device under high shear conditions to produce a protein-based drug nanocarrier containing the one or more psychedelic agents.

The application provides a kind of construction and application of multi-stage targeted carrier of viral antigen and adjuvant.It is a kind of nanometer loading SARS-CoV-2 and other viral recombinant protein antigens and vaccine adjuvant Toll-like receptor agonists by using liposome, solid lipid nanoparticle, nanoemulsion, polymer micelle and nanocapsule, etc., the surface of the nanocarrier is modified by using mannose and cationic peptide Par, and the nanocarrier is endowed with multi-stage targeting of dendritic cells and endoplasmic reticulum.By adjusting the ratio of Man and Par, the processing of SARS-CoV-2 and other viral recombinant protein antigens in the endoplasmic reticulum and lysosome of DC cells can be effectively regulated, the presentation of exogenous antigens by DC cells is enhanced, and the initiation of CD8+ and CD4+ T cells in the body is promoted; meanwhile, the nanocarrier can also deliver very low dose of CpG-OND adjuvant directly to the endoplasmic reticulum of DC cells to play a role, and the potential immunotoxicity induced by the adjuvant is reduced.

Disclosed herein are formulated and / or co-formulated liposomes, lipid nanoparticles (LNPs), and solid lipid nanoparticles (SLNPs) comprising a TB prodrug, as well as methods of making the LNPs and the SLNPs. The TB prodrug composition includes a drug moiety, a lipid moiety, and a linking unit that inhibits ALK5. The TB prodrugs may be formulated and / or co-formulated into nanocarriers to provide methods of treating cancer, immune disorders, and other diseases by utilizing targeted drug delivery vehicles.

Disclosed herein are solid lipid nanoparticles comprising a fatty acid esterified with polyethylene glycol. The polyethylene glycol is functionalised with an aptamer (i.e. targeting ligand). The nanoparticle may be loaded with an antibiotic or an antifungal, and a fluorescent compound. Also provided are their methods of preparation and their use in drug delivery and biosensing.

The application belongs to the technical field of preparation, and particularly relates to solid lipid nanoparticles for wrapping hydroxytyrosol and a preparation method and application thereof. The application realizes that the hydroxytyrosol is dissolved in oil by adjusting the pH value to create an acid environment, and further provides the possibility of wrapping the hydroxytyrosol by oil. The hydroxytyrosol is wrapped by solid oil, and further, the solid lipid nanoparticle emulsion is prepared, so that the stability of the hydroxytyrosol is significantly improved.

The invention discloses resveratrol solid lipid nanoparticles and application thereof in preparation of drugs for treating hepatic fibrosis, belongs to the technical field of drugs for treating hepatic fibrosis, and explains a regulation mechanism of the resveratrol solid lipid nanoparticles for resisting rat hepatic fibrosis in vivo and in vitro. Through CCK-8, cell scratches and Transwell experiments, the influence of the novel nano dosage form on the proliferation, migration and invasion ability of rat hepatic stellate cells (HSC-T6) is detected; an Annexin V-FITC / PI and ROS kit is used for determining the influence of the nano dosage form on the HSC-T6 apoptosis, the period and the ROS content; immunofluorescence and western-blot are used for detecting the influence of a new nano dosage form on the expression content of a hepatic fibrosis specific marker of HSC, and it is found that the resveratrol solid lipid nanoparticles can effectively inhibit proliferation of rat HSC-T6 cells, induce HSC-T6 cell apoptosis, inhibit migration and invasion and regulate alpha-SMA expression. The resveratrol solid lipid nanoparticles can inhibit the activation of hepatic stellate cells and achieve the effect of resisting rat hepatic fibrosis by influencing a signal channel of TGF-beta / smad2.

A particle includes at least one or more kinds of substrate and lipid nanoparticles. The lipid nanoparticles are dispersed in the substrate and contain a physiologically active substance. The lipid nanoparticles are one or more kinds selected from liposomes, lipid emulsions, and solid lipid nanoparticles. A corresponding powder inhalant contains the particle. A production method for the particle includes granulating and drying, in which a suspension containing the substrate and the lipid nanoparticles are granulated and dried in a gas medium.

The invention belongs to the field of yoghurt preparation, and particularly relates to stirring type composite yoghurt and a preparation method thereof. Wherein the composite additive relates to solid lipid nanoparticles prepared from fruit and vegetable paste, curcumin and the like, gel particles treated by glutaminase and hydroxypropyl starch, and the composite additive obtained by mixing the solid lipid nanoparticles, the gel particles and the hydroxypropyl starch can improve the conditions of whey precipitation and the like of the stirred yoghurt; the freeze-dried composition is obtained by treating limited species numbers of fruits, vegetables and cereals and carrying out microwave spray drying in the presence of reagents such as sodium caseinate, the obtained freeze-dried composition is large in gap, and flavor fusion can be rapidly achieved in the stirring process when the freeze-dried composition is added into stirred yogurt; lactobacillus delbrueckii subsp. Bulgaricus and lactococcus lactis subsp. Lactis are used as fermentation agents, and three-stage fermentation processes are involved, so that the quality of the stirring type compound yoghourt can be improved. The stirring type compound yoghourt obtained by the preparation method disclosed by the invention has relatively high in-vitro antioxidant activity and a relatively good eating effect.

The invention discloses sinomenine hydrochloride solid lipid nanoparticles, gel, a preparation method and application, by exploring the preparation method of the sinomenine hydrochloride solid lipid nanoparticles HA-SH-SLNs, when the mass ratio of sinomenine hydrochloride to soya bean lecithin to hyaluronic acid modified targeting molecule DSPE-PEG-HA to poloxamer Pluronic F-68 is (0.3-0.7): (1-4): (0.0125-0.1): (1-4), the gel can be used for preparing the sinomenine hydrochloride solid lipid nanoparticles HA-SH-SLNs. The sinomenine hydrochloride solid lipid nanoparticles which are uniform in particle size, high in encapsulation efficiency, high in drug loading capacity and stable in quality are obtained, and the preparation method of the sinomenine hydrochloride solid lipid nanoparticle gel is further researched. The obtained sinomenine hydrochloride solid lipid nanoparticle gel HA-SH-SLNs-Gel is good in stability and small in hemolysis rate, the in-vivo residence time is longer than that of sinomenine hydrochloride solid lipid nanoparticles, the drug release period is delayed, and better articular cavity injection administration is facilitated.

The present invention relates to a genetic material carrier for transdermal delivery and a composition for preventing or treating cancer, comprising same. The genetic material carrier according to the present invention can promote the transdermal delivery of a genetic material and target cancer cells and has appropriate nano-size distribution and minimum non-specific cytotoxicity, by coating, with hyaluronic acid (HA), cationic solid lipid nanoparticles (CSLNs) that carry angiogenesis-inhibiting siVEGF, and thus can be used as a novel transdermal drug carrier for targeted cancer therapy.

This invention relates to liposomes having mucopenetrating action and rates of incorporation of a retinoid, for example retinoic acid (RA), greater than those obtained in solid lipid nanoparticles (0.1%), thus increasing the uptake thereof via the nasal mucosa, and to the method for preparing a liposome. The present invention also relates to an intranasal composition, for example a vaccine, comprising said liposome, which is more effective than existing vaccines, the method for preparing same and the use thereof for preventing illnesses.

Provided herein is a process for preparing solid lipid nanoparticles of curcumin. Also provided herein are solid lipid nanoparticles of curcumin having a particle size in the range of 20-800 nm. The solid lipid nanoparticles of curcumin show a very high entrapment efficiency of curcumin in the range of 50-100% in terms of actual curcumin content of the formulation. The solid lipid nanoparticles of curcumin show increased efficacy of the curcumin.

The invention relates to a preparation method of microbial enzyme response solid lipid nanoparticles for treating UC, which realizes efficient targeted drug delivery through a three-step core process: firstly, taking refined cotton as a raw material at an ultralow temperature of-40 DEG C, mixing concentrated sulfuric acid and n-propyl alcohol according to a ratio of 1: 9 with a vulcanizing agent, carrying out sulfonation reaction for 24 hours, and carrying out alkalization and purification to obtain anionic polyelectrolyte NaCS; secondly, suspending NaCS in a pyridine solution, reacting with lauroyl chloride in a water bath at 80 DEG C according to a molar ratio of 1: 1.2, carrying out alcohol precipitation by using 85% ethanol, repeatedly dissolving, precipitating and purifying by using tetrahydrofuran and ethanol, and carrying out vacuum drying to obtain a hydrophobic modified product NaCS-C12; finally, multi-layer polyelectrolyte coating is completed through a layer-by-layer self-assembly technology, zeta potential change is monitored to ensure saturated adsorption, and three-layer polyelectrolyte compound coating is formed, so that microbial enzyme responsive targeted release is realized; the method has remarkable advantages, drug release is triggered by utilizing activity difference of colon cellulase, and focus targeting and drug effect are improved; the PEC layer is composed of a natural degradable polymer, so that the biocompatibility is enhanced, the toxicity is low, and no organic solvent is left; the solid lipid nanoparticles improve the drug loading capacity, promote accumulation of inflammation sites, and overcome the defects of early quick release and single polysaccharide film formation in the prior art.

The present application relates to formulated and / or co-formulated liposome compositions containing TFG [beta] antagonist prodrugs and methods thereof that can be used to treat cancer. Disclosed herein are formulated and / or co-formulated lipid nanoparticles (LNPs) and solid lipid nanoparticles (SLNPs) comprising a TB prodrug and methods of making the LNPs and the SLNPs. The TB prodrug composition comprises a drug part, a lipid part and a connecting unit, and the TB prodrug composition inhibits ALK5. The TB prodrugs may be formulated and / or co-formulated into liposomes or solid lipid nanoparticles to provide methods of treating cancer, immune disorders, and other diseases by utilizing targeted drug delivery vehicles.

The present application relates to ionizable lipid compounds containing borneol structure and its preparation method and application, and belongs to the technical field of biological medicine. The present application introduces polyamine structure and hydrophobic tail chain by modifying the hydroxyl group at C2 position of borneol molecule, and prepares a new type of ionizable lipid compounds containing borneol structure. The compound has the following advantages: (i) the borneol structure can effectively break through the skin keratin layer barrier and significantly improve the transdermal absorption efficiency; (ii) the polyamine structure can be ionized under acidic conditions, efficiently carry nucleic acid drugs through electrostatic adsorption, help to enhance the stability of nucleic acid and promote lysosome escape; (iii) the tail chain modification enhances the liposolubility of the compound, endows it with lipid characteristics, and can be used as a raw material for the preparation of solid lipid nanoparticles. The present application also provides a preparation method of the compound, and the ionizable lipid compounds containing borneol structure show good application prospect in the field of transdermal delivery of nucleic acid drugs.